Maravai LifeSciences vs Prenetics Global
MRVI and PRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MRVI and PRE compare
Prenetics Global grew revenue faster over the last twelve months (480% versus 10.7% for Maravai LifeSciences).
Maravai LifeSciences keeps more of each dollar of sales as profit, with a net margin of −30.8% compared with −40.8% at Prenetics Global.
Prenetics Global scores higher on the StockData Score (10 against 8 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MRVI | PRE |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | – |
| Share price | $7.70 | $17.64 |
| Change, 1 year | 148% | 48.4% |
| Change, 5 years | −79.4% | −88.1% |
| Beta (5Y) | 1.02 | 0.60 |
| Employees | 435 | 98 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.4× | – |
| P/B | 10.2× | – |
| FCF yield | −0.66% | – |
| Fair value | $2.66 | – |
| Margin of safety | −190% | – |
| Growth | ||
| Revenue growth (TTM) | 10.7% | 480% (better) |
| Revenue growth, 5Y average | −8.1% | 7.2% (better) |
| Profitability | ||
| Gross margin | 39.1% | 52.8% (better) |
| Operating margin | −45.4% (better) | −48.1% |
| Net margin | −30.8% (better) | −40.8% |
| FCF margin | −6.2% (better) | −23.8% |
| Return on equity | −29.8% | −23.1% (better) |
| Return on invested capital | −27.0% (better) | −29.0% |
| Financial health | ||
| Debt / equity | 0.75 (better) | 0.00 |
| Interest coverage | −4.6× | – |
| Current ratio | 4.66 (better) | 2.97 |
| Altman Z-score | 4.63 | – |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 55.5% | – |
| Held by insiders | 54.1% | 14.2% |
| Insider net buying, 12 months | $115K | $1000K (better) |
| Short interest, % of float | 11.8% | – |
Go deeper
- MRVI stock overview
- MRVI income statement
- MRVI valuation and score
- PRE stock overview
- PRE income statement
- PRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.